Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer announces update to its development pipeline

Pfizer announces update to its development pipeline

28th January 2010

Pfizer has revealed changes to its research and development pipeline for the first time since it acquired fellow pharmaceutical firm Wyeth last October.

The new pipeline comprises assets from both organisations and includes a total of 133 programmes from phase I through to registration.

Martin Mackay, president of pharmatherapeutics research and development at Pfizer, stated that since the acquisition of Wyeth, a number of strategic decisions regarding the company’s “research and development resources, global footprint and high-priority projects” have been made.

“This pipeline of investigational medicines represents the strong future of Pfizer. Our focus now turns to delivery of these health solutions for patients around the world,” he furthered.

Meanwhile, Pfizer announced this week that a phase III clinical study into Sutent (sunitinib malat) – its drug designed to hinder the growth of advanced pancreatic neuroendocrine tumours – yielded promising results.

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips and straight to your inbox.